6 results
6-K
EX-99
BLRX
Bioline Rx Ltd
10 Apr 24
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million
7:24am
to be used to further accelerate uptake of APHEXDA® in stem cell mobilization, life-cycle expansion activities in sickle cell disease … , accelerate APHEXDA life-cycle programs in sickle cell disease and other areas, and support development of motixafortide in metastatic pancreatic cancer
6-K
EX-99.1
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
with the APHEXDA launch and advancing key life cycle programs for long-term growth opportunities”, said Philip Serlin, Chief Executive Officer of BioLineRx
20-F/A
2023 FY
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
of action for motixafortide, generate data about motixafortide’s potential use in other indications, and inform the life-cycle management process … of motixafortide, and a life-cycle expansion and management program for other therapeutic indications for motixafortide, our future research and development
6-K
EX-99
BLRX
Bioline Rx Ltd
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
indications, and inform the life-cycle management process of motixafortide. The results of studies such as these are presented from time to time at relevant
6-K
EX-99
o3ycwgr
15 Sep 22
Current report (foreign)
8:39am
- Prev
- 1
- Next